Precision remedy, the place medicines change into ever extra particular to sure mutations in sure tumors, is commonly touted as the way forward for oncology. However a brand new firm known as Dispatch Bio is taking the alternative strategy and attempting to go as vast as attainable. As a substitute of tailoring the appropriate remedy to the appropriate affected person, Dispatch is growing a brand new, common strategy to attempt to deal with any most cancers utilizing immunotherapy.
The important thing to this strategy is an artificial protein, known as the “flare” antigen, which Dispatch’s remedy goals to put in on each most cancers cell in a affected person’s physique. As soon as there, the corporate can direct immunotherapies to assault that protein and kill the most cancers carrying it, wherever it’s within the physique and no matter most cancers kind it might be.
“Too many methods which have come earlier than appear to resolve a single drawback or a single illness,” Lex Johnson, the Dispatch’s chief platform officer, stated in a video on the corporate’s web site. “The universality of Dispatch’s strategy is actually derived from the engineering we did round this distinctive flare protein.”
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
